Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Finished Goods (2023 - 2025)

Tg Therapeutics (TGTX) has 3 years of Finished Goods data on record, last reported at $21.1 million in Q3 2025.

  • For Q3 2025, Finished Goods rose 164.86% year-over-year to $21.1 million; the TTM value through Sep 2025 reached $21.1 million, up 164.86%, while the annual FY2024 figure was $13.9 million, 597.25% up from the prior year.
  • Finished Goods reached $21.1 million in Q3 2025 per TGTX's latest filing, down from $21.8 million in the prior quarter.
  • Across five years, Finished Goods topped out at $21.8 million in Q2 2025 and bottomed at $52000.0 in Q1 2023.
  • Average Finished Goods over 3 years is $7.5 million, with a median of $2.0 million recorded in 2023.
  • The widest YoY moves for Finished Goods: up 3559.62% in 2024, down 145.07% in 2024.
  • A 3-year view of Finished Goods shows it stood at $2.0 million in 2023, then skyrocketed by 597.25% to $13.9 million in 2024, then soared by 51.3% to $21.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $21.1 million in Q3 2025, $21.8 million in Q2 2025, and $10.7 million in Q1 2025.